Kamal S. Saini: Enrollment is Ongoing for Phase 3 study CAMBRIA-1

Kamal S. Saini, Executive Medical Director and Head of European Medical Oncology Team at Fortrea Inc., made the following post on LinkedIn

“Approximately 4300 pts will be randomized into the early breast cancer Phase 3 study CAMBRIA-1; enrollment is ongoing!

A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2– early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
Erika Hamilton; Sibylle Loibl; Naoki Niikura; Priya Rastogi; Kamal S. Saini; Ioanna Gioni; Teresa Klinowska; Ingrid A. Mayer; Mary Stuart; Emilia Syta; Andrew Walding; Thomas Bachelot.”

Read further.
Source: Kamal S. Saini/LinkedIn
.